MAP Pharmaceuticals Acquired By Allergan
Mountain View-based MAP Pharmaceuticals, a publicly held developer of biopharmaceuticals aimed at treating migraines in adults, has been acquired by Allergan. The two said that Allergan will pay $25.00 per share for MAP, or approximately $958M, in the deal. Allergan was advised by Goldman, Sachs & Co. and Gibson, Dunn & Crutcher LLP in the deal; MAP Pharmaceuticals was advised by Centerview Partners LLC and Latham & Watkins LLP.
posted on Wednesday, January 23, 2013
Related companies:
Map My Customers, Inc.
Related stories:
> Tobira Therapeutics Acquired By Allergan For $1.7B
> Oculeve Acquired By Allergan For $125M
> ZELTIQ Acquired By Allergan For $2.47 Billion
> Alexza Pharmaceuticals Acquired By Ferrer
> KAI Pharmaceuticals Acquired By Amgen For $315M
silicontap.com Home